Literature DB >> 19544378

Revisiting the role of positron-emission tomography/computed tomography in determining the need for planned neck dissection following chemoradiation for advanced head and neck cancer.

Christine G Gourin1, Brian J Boyce, Hadyn T Williams, Anne V Herdman, Paul A Bilodeau, Teresa A Coleman.   

Abstract

OBJECTIVES/HYPOTHESIS: Planned neck dissection following chemoradiation (CR) has been advocated in patients with head and neck squamous cell cancer (HNSCC) with advanced nodal disease and a clinical complete response to CR because of the potential for residual occult nodal disease. The utility of positron-emission tomography/computed tomography (PET-CT) in identifying occult nodal disease in this scenario is controversial.
METHODS: The medical records of all patients treated with CR for advanced HNSCC with N2 or N3 disease from December 2003 to June 2007 were reviewed. Patients with a complete clinical response were included if PET-CT performed 8 to 11 weeks after CR showed no distant disease and they underwent planned neck dissection.
RESULTS: Thirty-two patients met study criteria. PET-CT was positive for residual nodal disease in 20 patients (63%). Pathology revealed carcinoma in 10 patients (31%): six of 20 patients with positive PET-CT scans (30%) and four of 12 patients with negative PET-CT scans (33%). The sensitivity and specificity of PET-CT was 60% and 36%. Regional recurrence developed in two patients (6%) who were not successfully salvaged.
CONCLUSIONS: PET-CT performed 8 to 11 weeks after CR does not reliably predict the need for planned post-treatment neck dissection in patients with a complete clinical response following CR. Regional recurrence rates are comparable to those reported for patients observed with PET-CT, suggesting no advantage for planned neck dissection, and salvage rates were poor. These data suggest that delaying the timing of PET-CT, with surgery reserved for positive findings, is a reasonable alternative to planned neck dissection to avoid unnecessary surgery.

Entities:  

Mesh:

Year:  2009        PMID: 19544378     DOI: 10.1002/lary.20523

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  9 in total

1.  Evaluation of neck node response after radiotherapy: minimizing equivocal results.

Authors:  Remco de Bree; Otto S Hoekstra
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04       Impact factor: 9.236

Review 2.  PET/CT in head and neck cancer: an update.

Authors:  Roland Hustinx; Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03       Impact factor: 9.236

3.  Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis.

Authors:  Tejpal Gupta; Zubin Master; Sadhana Kannan; Jai Prakash Agarwal; Sarbani Ghsoh-Laskar; Venkatesh Rangarajan; Vedang Murthy; Ashwini Budrukkar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-19       Impact factor: 9.236

4.  Head and neck PET/CT therapy response interpretation criteria (Hopkins criteria) - external validation study.

Authors:  Ayse Tuba Kendi; David Brandon; Jeffrey Switchenko; Jeffery Trad Wadsworth; Mark W El-Deiry; Nabil F Saba; David M Schuster; Rathan M Subramaniam
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-09-01

Review 5.  Positron emission tomography for neck evaluation following definitive treatment with chemoradiotherapy for locoregionally advanced head and neck squamous cell carcinoma.

Authors:  Voichita Bar-Ad; Mark Mishra; Nitin Ohri; Charles Intenzo
Journal:  Rev Recent Clin Trials       Date:  2012-02

6.  Role of positron emission tomography in the treatment of occult disease in head-and-neck cancer: a modeling approach.

Authors:  Mark H Phillips; Wade P Smith; Upendra Parvathaneni; George E Laramore
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-25       Impact factor: 7.038

7.  Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes.

Authors:  Charles Marcus; Anthony Ciarallo; Abdel K Tahari; Esther Mena; Wayne Koch; Richard L Wahl; Ana P Kiess; Hyunseok Kang; Rathan M Subramaniam
Journal:  J Nucl Med       Date:  2014-06-19       Impact factor: 10.057

8.  FDG-PET/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance.

Authors:  Nils Helsen; Tim Van den Wyngaert; Laurens Carp; Sigrid Stroobants
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-24       Impact factor: 9.236

9.  Clinical significance of the post-radiotherapy 18F-fludeoxyglucose positron emission tomography response in nasopharyngeal carcinoma.

Authors:  Yuri Jeong; In-Hye Jung; Jae Seung Kim; Sei Kyung Chang; Sang-Wook Lee
Journal:  Br J Radiol       Date:  2019-01-03       Impact factor: 3.039

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.